GLP-1 Agonists, Like Ozempic and Wegovy, Have Risk of Gut Issues: Study

The use of glucagon-like peptide 1 (GLP-1) agonists for weight loss, such as Novo Nordisk’s Ozempic and Wegovy, is associated with the risk of gastrointestinal adverse events, according to a study published Thursday in the medical journal JAMA.